Big data: the next frontier for innovation in therapeutics and healthcare

Advancements in genomics and personalized medicine not only effect healthcare delivery from patient and provider standpoints, but also reshape biomedical discovery. We are in the era of the ‘-omics’, wherein an individual’s genome, transcriptome, proteome and metabolome can be scrutinized to the finest resolution to paint a personalized biochemical fingerprint that enables tailored treatments, prognoses, risk factors, etc. Digitization of this information parlays into ‘big data’ informatics-driven evidence-based medical practice. While individualized patient management is a key beneficiary of next-generation medical informatics, this data also harbors a wealth of novel therapeutic discoveries waiting to be uncovered. ‘Big data’ informatics allows for networks-driven systems pharmacodynamics whereby drug information can be coupled to cellular- and organ-level physiology for determining whole-body outcomes. Patient ‘-omics’ data can be integrated for ontology-based data-mining for the discovery of new biological associations and drug targets. Here we highlight the potential of ‘big data’ informatics for clinical pharmacology.

[1]  Rong Xu,et al.  Toward creation of a cancer drug toxicity knowledge base: automatically extracting cancer drug-side effect relationships from the literature , 2014, J. Am. Medical Informatics Assoc..

[2]  J. Lindon,et al.  Pharmaco-metabonomic phenotyping and personalized drug treatment , 2006, Nature.

[3]  J. Hare,et al.  The use of transcriptomic biomarkers for personalized medicine , 2007, Heart Failure Reviews.

[4]  Barend Mons,et al.  Generic Information Can Retrieve Known Biological Associations: Implications for Biomedical Knowledge Discovery , 2013, PloS one.

[5]  David A. Hanauer,et al.  Exploring Clinical Associations Using ‘-Omics’ Based Enrichment Analyses , 2009, PloS one.

[6]  R. Weiss,et al.  Urine metabolomics for kidney cancer detection and biomarker discovery. , 2011, Urologic oncology.

[7]  Antoni Ribas,et al.  Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. , 2014, Cancer discovery.

[8]  M. Fava,et al.  QT interval and antidepressant use: a cross sectional study of electronic health records , 2013, BMJ.

[9]  David E Root,et al.  Global analysis of large-scale chemical and biological experiments. , 2002, Current opinion in drug discovery & development.

[10]  R. Weiss,et al.  New opportunities from the cancer metabolome. , 2013, Clinical chemistry.

[11]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[12]  Felix W Frueh,et al.  Impact of Proton Pump Inhibitors on the Effectiveness of Clopidogrel After Coronary Stent Placement: The Clopidogrel Medco Outcomes Study , 2010, Pharmacotherapy.

[13]  A. Barabasi,et al.  Network biology: understanding the cell's functional organization , 2004, Nature Reviews Genetics.

[14]  E. Petricoin,et al.  Clinical proteomics: personalized molecular medicine. , 2001, JAMA.

[15]  George M. Church,et al.  Raw Personal Data: Providing Access , 2014, Science.

[16]  Li-Rong Yu,et al.  Quantitative proteomics for drug toxicity. , 2009, Briefings in functional genomics & proteomics.

[17]  J. Nicholson,et al.  Genetic determinants of metabolism in health and disease: from biochemical genetics to genome-wide associations , 2012, Genome Medicine.

[18]  Oakland J. Peters,et al.  Predicting new indications for approved drugs using a proteochemometric method. , 2012, Journal of medicinal chemistry.